ライフサイエンスコーパス: thrombopoiesis

1 megakaryocyte specification, maturation, and thrombopoiesis.

2 ematopoietic lineage commitment and enhanced thrombopoiesis.

3 role of NO in megakaryocyte development and thrombopoiesis.

4 y also provide novel molecular insights into thrombopoiesis.

5 mbocytopenia, and measurement of the rate of thrombopoiesis.

6 te to our understanding of the regulation of thrombopoiesis.

7 larger platelets, rather than suppression of thrombopoiesis.

8 ibution of these cytokines to suppression of thrombopoiesis.

9 ncipal regulator of megakaryocytopoiesis and thrombopoiesis.

10 led a previously unappreciated complexity in thrombopoiesis.

11 ys a major role in MK membrane formation and thrombopoiesis.

12 expression would affect megakaryopoiesis and thrombopoiesis.

13 tional repressor of adult erythropoiesis and thrombopoiesis.

14 r niche, the site of terminal maturation and thrombopoiesis.

15 ing that RUNX1B can regulate endomitosis and thrombopoiesis.

16 and synergistic effect with c-Mpl ligands on thrombopoiesis.

17 lar proplatelet shedding, the final stage of thrombopoiesis.

18 ion, itself controlling megakaryopoiesis and thrombopoiesis.

19 telet count was compensated for by increased thrombopoiesis.

20 use bone marrows revealed exceedingly active thrombopoiesis.

21 oidal endothelial cells (BMECs), stimulating thrombopoiesis.

22 randomly transfer, mRNA to platelets during thrombopoiesis.

23 yet another function of this lipid mediator: thrombopoiesis.

24 i-D and IVIG, although IVIG may also enhance thrombopoiesis.

25 of MT regulation during the final stages of thrombopoiesis.

26 gesting that c-myb is required for sustained thrombopoiesis.

27 ombopoietin-receptor agonist that stimulates thrombopoiesis.

28 eport a role for the glycoprotein PECAM-1 in thrombopoiesis.

29 pathways that regulate megakaryopoiesis and thrombopoiesis.

30 ad to new molecular approaches to manipulate thrombopoiesis.

31 shear stress is a biophysical determinant of thrombopoiesis.

32 e for PECAM-1 in regulating MK migration and thrombopoiesis.

33 al MT bands; thus, SLPI is not essential for thrombopoiesis.

34 instructive for megakaryocyte maturation and thrombopoiesis.

35 (NF-E2), a transcription factor required for thrombopoiesis.

36 itor the DMS during megakaryocytopoiesis and thrombopoiesis.

37 ibute to normal megakaryocyte maturation and thrombopoiesis.

38 ci to track donor-derived erythropoiesis and thrombopoiesis.

39 tion was disrupted, resulting in an impaired thrombopoiesis and an abrogated inositol 1,4,5-triphosph

40 ricted beta1 tubulin is required for optimal thrombopoiesis and discoid cell shape.

41 The developed compartmental model of thrombopoiesis and erythropoiesis in a BM toxicity conte

42 A compartmental model of mouse thrombopoiesis and erythropoiesis was set up to predict

43 g of autoantibody development, inhibition of thrombopoiesis and Fcgamma receptor and other polymorphi

44 ld be exploited to study normal and abnormal thrombopoiesis and for in vitro platelet production.

45 -S1pr1 axis as master regulator of efficient thrombopoiesis and might raise new therapeutic options f

46 HFRS patients have increased thrombopoiesis and platelet activation, which contribute

47 provide a useful means for evaluating human thrombopoiesis and platelet function in vivo using immun

48 nctional role of growth hormone in promoting thrombopoiesis and provide a promising avenue for the tr

49 of the specialized microtubules required in thrombopoiesis and that RanBP10 might serve as a molecul

50 The exact mechanism of thrombopoiesis and the maturation pathways of platelets

51 To better understand thrombopoiesis and to develop a potential platelet trans

52 ain causes for thrombocytopenia are impaired thrombopoiesis and/or increased peripheral destruction o

53 2-dependent endocytosis in megakaryopoiesis, thrombopoiesis, and bone marrow homeostasis.

54 ate that proteasome function is critical for thrombopoiesis, and suggest inhibition of RhoA signaling

55 (dominant proinflammatory state, inadequate thrombopoiesis, and various B and T lymphocyte disturban

56 The regulation of megakaryocytopoiesis and thrombopoiesis appears to be under the control of an arr

57 ng megakaryopoiesis and platelet production (thrombopoiesis) are still incompletely understood.

58 sis appears to result from an enhancement of thrombopoiesis because platelet life span is unchanged.

59 duced by M-CSF was not due to suppression of thrombopoiesis, but to increased activity of the monocyt

60 latelet responses to activation and regulate thrombopoiesis by a negative regulatory effect on premat

61 eal CK2beta as a novel powerful regulator of thrombopoiesis, Ca(2+)-dependent platelet activation, an

62 The relative sparing of thrombopoiesis can be seen in that only one patient (5%)

63 arrow milieu, it raises the possibility that thrombopoiesis continues in the bloodstream.

64 ided by factor H protection and compensatory thrombopoiesis demonstrates the cooperation between memb

65 TSPs inhibited thrombopoiesis, diminished bone marrow microvascular rec

66 mean platelet volume all indicate increased thrombopoiesis during HFRS.

67 wever, the S1P(4) receptor may also regulate thrombopoiesis during stress-induced accelerated platele

68 irus liganding is dispensable for definitive thrombopoiesis, establishing that fundamentally importan

69 tudy supports a major role for the spleen in thrombopoiesis following engraftment of transplanted ste

70 The study of thrombopoiesis has evolved greatly since an era when pla

71 ved in various cellular processes, a role in thrombopoiesis has not been examined.

72 aintenance of bone marrow erythropoiesis and thrombopoiesis have not been defined.

73 fibroblast growth factor-4 (FGF-4), restored thrombopoiesis in Thpo(-/-) and Mpl(-/-) mice.

74 increase in MK numbers, indicating increased thrombopoiesis in vivo.

75 Possible mediators of suppression of thrombopoiesis include tumor necrosis factor-alpha (TNF-

76 trated the ability to reproduce key steps of thrombopoiesis, including alterations observed in diseas

77 Thrombopoiesis is the process by which megakaryocytes re

78 hematopoiesis, although its direct effect on thrombopoiesis is unclear.

79 Surprisingly, steady-state thrombopoiesis is unperturbed in the absence of caspase-

80 rombopoietin (TPO), the primary regulator of thrombopoiesis, is also an important, nonredundant media

81 ombopoietin-receptor agonist that stimulates thrombopoiesis, leading to increased platelet production

82 of thrombopoietin mimetic peptide (dTMP) on thrombopoiesis, manifested by a significant acceleration

83 During thrombopoiesis, maturing megakaryocytes (MKs) migrate wi

84 During thrombopoiesis, megakaroycytes undergo extensive cytoske

85 n-IIA and implies that myosin-IIA influences thrombopoiesis negatively.

86 rmation should provide greater insights into thrombopoiesis, potentially allowing pharmacologic manip

87 mbocytopenia as a consequence of ineffective thrombopoiesis, promoting MK differentiation but also im

88 In conclusion, A-IPF measures real-time thrombopoiesis, providing insight into mechanisms of tre

89 The induced perturbation in steady state thrombopoiesis resolves by 4 weeks.

90 marker panel using mouse models of defective thrombopoiesis resulting from absence of GATA1, NF-E2, o

91 2 weeks of murine life, a time during which thrombopoiesis shifted from liver to bone marrow.

92 dexamethasone and anti-D immunoglobulin, and thrombopoiesis-stimulating agents that are in early clin

93 In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients

94 In previous studies romiplostim (AMG531), a thrombopoiesis-stimulating protein, increased platelet c

95 Short-term administration of the thrombopoiesis-stimulating protein, romiplostim, has bee

96 In vivo visualization of thrombopoiesis suggests an important role for shear flow

97 nisms underlying normal megakaryopoiesis and thrombopoiesis that can inform efforts to create alterna

98 e identification of the primary regulator of thrombopoiesis, the Mpl ligand, has led to an explosion

99 Thrombopoiesis, the process by which circulating platele

100 ated the role of exogenous ABA in modulating thrombopoiesis, the process of platelet generation.

101 Our understanding of thrombopoiesis--the formation of blood platelets--has im

102 erence with megakaryocyte motility inhibited thrombopoiesis under physiological conditions and after

103 gosine 1-phosphate (S1P) plays a key role in thrombopoiesis via its receptor S1pr1.

104 of dynamin activity to the latter stages of thrombopoiesis was confirmed by the observation that the

105 Thrombopoiesis was determined by quantification of plate

106 To determine the role of DNM2 in thrombopoiesis, we generated Dnm2(fl/fl) Pf4-Cre mice sp

107 advantage of known physiological drivers of thrombopoiesis, we have developed a microfluidic human p

108 he source of intracellular S1P that controls thrombopoiesis, which is associated with SFK expression

109 akaryocytes, the requisite precursor cell in thrombopoiesis, which is the intricate process by which

110 re virtually assured that continued study of thrombopoiesis will yield innumerable clinical and scien

111 tely increase MK-vasculature association and thrombopoiesis with no change in MK number.

112 d splice-blocking PEAR1 morpholinos enhanced thrombopoiesis, without affecting erythropoiesis.